SMA Screening Now Available to 87% of Newborns in US

Screening for spinal muscular atrophy (SMA), the leading genetic cause of infant death, is now available to 87% of all babies born in the United States, according to Cure SMA. The milestone was reached after Arizona and Louisiana began testing newborns for SMA this year, raising the number of states with the screening to 40.

Cure SMA conveyed the news in a Jan. 27 tweet: “Starting out 2022 strong! This month, Arizona and Louisiana officially begin screening newborns for spinal muscular atrophy. With these implementations, 87% of newborns in the U.S. are now being screened for SMA.” This comes four years after SMA was added to the federal Recommended Uniform Screening Panel (RUSP).